45 results about "Minimal Brain Dysfunction" patented technology

A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided.

A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.

The invention provides methods for diagnosing, assessing or quantitating drug use, drug abuse or narcosis or for differentiating drug use, drug abuse or narcosis from brain injury in a subject by tracking eye movement of at least one eye of the subject, analyzing eye movement of at least one eye of the subject, comparing eye movement of at least one eye of the subject the normal or mean eye movement; and, optionally calculating a standard deviation or p value for eye movement of at least one eye of the subject as compared to the normal or mean eye movement.

A Chinese medicine for treating child minimal brain dysfunction is prepared from 6 Chinese medicinal materials including ginseng, astragalus root, tuckahoe, liquorice root, etc. through proportioning, compounding according to different characters of medicines crushing, immersing, decocting, drying and bottling. Its advantages are high curative effect, no toxic by-effect and low cost.

The invention specifically relates to a children attention deficit hyperactivity disorder treatment system. The children attention deficit hyperactivity disorder treatment system comprises a treatment device and a treatment system. The treatment system comprises an evaluation module and a training and treatment module. The evaluation module is used for judging the executive function deficit degree and the ADHD symptom serious degree, and screening out potential psychological problems, and the evaluation result provides essential data for the training and treatment module. The training and treatment module is inside provided with a mind-brain cognitive training and treatment project, and is used for training and treating a plurality of core domains of the executive function, and improving each capacity in the executive function of the patient in order to eliminate each disease of children with cognitive disorder. The children attention deficit hyperactivity disorder treatment system is a domestic first training and treatment system which is researched and developed aiming at the executive function problems of ADHD child patients, a safe and noninvasive principle is employed, a non-drug intervention method is explored deeply, a brand new clinical treatment selection is provided for lots of patients, and the children attention deficit hyperactivity disorder treatment system can be applied to healthy children and children with executive function defects, thereby improving the expression of the children on executive function tasks.

A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concerta®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including serotonin receptors and dopamine receptors. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, and senile dementia.

The present invention is concerned with deuterium-enriched isobutyl and cyclohexylmethyl sulfonamides of formula I and II, and pharmaceutically acceptable salts and methods of use thereof for the treatment of general anxiety disorders, major depressive disorders, attention deficit disorders, attention deficit hyperactivity disorder, Alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, schizophrenia, migraine, sleep disorders, neurodegenerative diseases and obesity.

The invention discloses a medicament for treating attention deficit hyperactivity disorder and a preparation method thereof. The medicament is mainly prepared from medicinal materials such as prepared rehmannia root, radix paeoniae alba, astragalus membranaceus, dragon bone, polygala tenuifolia, rhizoma acori graminei, angelica sinensis, uncaria and liquorice in a certain weight proportion. The medicament disclosed by the invention has the functions of calming the nerves, promoting the intelligence, clearing heat, calming the liver, calming endogenous wind and arresting convulsion; the medicament is quick in taking effect in treating attention deficit hyperactivity disorder and good in curative effect without side effects.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating attention deficit hyperactivity disorder in children and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine composition comprises root of heterophylla falsestarwort, processed rehmannia root, fruit of barbary wolfberry, fruit of Chinese magnoliavine, root of thinleaf milkwort, rhizome of tatarinowii sweetflag, and Poria. The traditional Chinese medicine composition prepared by using the preparation method according to the invention can act better, and is suitable for child patients to take often clinically.

The present invention relates to a method of treating attention deficit hyperactivity disorder in a subject. This method includes selecting a subject with attention deficit hyperactivity disorder and administering to the selected subject a sodium / hydrogen exchanger inhibitor under conditions effective to treat the subject for attention deficit hyperactivity disorder. Methods of identifying compounds suitable to treat attention deficit hyperactivity disorder are also disclosed.

The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. [Formula should be inserted here] The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor.; Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.

This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.

A fidget spinner is a designed combination, wherein a two-way or multi-way symmetrical body serves as a main body, a bearing is embedded in the middle of the main body, and the whole fidget spinner forms a novel article capable of rotation in a plane; the basic principle of the fidget spinner is similar to that of a traditional gyro, but it is necessary to use several fingers for holding and shifting the fidget spinner to make the fidget spinner rotate. From the beginning of 2016, the fidget spinner comes into fashion in north America, many people think that the fidget spinner can be helpful to alleviate the attention deficit hyperactivity disorder, the obsessive-compulsive disorder, the anxiety, absent-minded symptoms, meditation and boredom, has the function of sedation and is a gadget for relieving the boredom. To achieve the effects, the rotation mainly depends on the fingers shifting the fidget spinner, but how to further improve the rotation speed of the fidget spinner to make the effects more outstanding is concerned about. According to the fidget spinner, a sliding part on the fidget spinner is adopted, when the fidget spinner rotates, the sliding part is controlled to slide inwards, according to the angular momentum conversation principle and the situations that the angular momentum is equal to the rotational inertia times the angular velocity and the rotational inertia of an object is in inverse proportion to the rotation speed, when the sliding part slides inwards in a retraction mode, the rotational inertia is reduced, and the angular velocity is increased, so that the rotation speed of the fidget spinner is increased.

The invention discloses an attention deficit hyperactivity disorder treatment method. The attention deficit hyperactivity disorder treatment method includes the steps of using a sensor for collecting brain biological signals; using a chip for filtering the collected biological signals and amplifying useful signals, and interpreting current concentration degree and relax degree parameters of a trainee through an algorithm; judging concentration capability levels to be weak, medium and strong; terminating treatment when the concentration capability level is strong; if the concentration capability level is weak or medium, adjusting a training method and difficulty level; activating nerve cell correlation and inducing synapse remolding to form a new neural circuit. The attention deficit hyperactivity disorder treatment method has the advantages that a non-medicine mode is used for treating the attention deficit hyperactivity disorder and improving children's concentration, and silent synapses are transformed into functional synapses through training to help children control impulsivity and mood, so that the purposes of treating the attention deficit hyperactivity disorder and improving the children's concentration are achieved, memory and learning efficiency are improved, and toxic and side effects and irreversible damage caused by medicine treatment are overcome.

The invention discloses a Chinese patent medicine for treating attention deficit hyperactivity disorder and a preparation method thereof, belonging to the field of traditional Chinese medicines. The Chinese patent medicine is used for treating the attention deficit hyperactivity disorder, and comprises the following components: 5-10g of salvia miltiorrhiza, 5-8g of glossy privet fruit, 4-6g of lycium barbarum, 1-2g of white paeony root, 5-10g of donkey-hide gelatin, 4-6g of tuber fleeceflower stem, 10-30g of powdered antler, 15-20g of fructus alpiniae oxyphyllae, 8-12g of prepared fleece flower root, 10-15g of rhizoma acori graminei, 0-4g of radix curcumae, 5-8g of honey-fried licorice root, 10-15g of Chinese-date, 10-15g of stiff silkworm, 1-3g of radix polygonati officinalis and 1-5g of keel. The medicinal materials and weight ratios are adopted, so that the Chinese patent medicine disclosed by the invention has the effects of nourishing liver and kidney, nourishing heart and blood, and calming and inducing resuscitation; the proper medicinal materials and weight proportion relationship are selected, so that the symptoms such as attention deficit hyperactivity disorder, inattention, emotion instability and other minimal brain dysfunctions of children patients are improved.

This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

The present application relates to compounds of formulawherein R1, R2, R3, R4, and n are defined hereinor to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

The present invention relates to amino-4-methyl imidazoles and pharmaceutically-acceptable salts thereof. The compound may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The present application relates to compounds of formulawherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

The present invention refers to diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD).

The invention discloses a medicament for treating attention deficit hyperactivity disorder and a preparation method thereof. The medicament comprises radix pseudostellariae, radix rehmanniae preparata, fructus lycii, Chinese magnoliavine fruits, radix polygalae, rhizoma acori graminei and poria cocos. The preparation method of the medicament for treating attention deficit hyperactivity disorder comprises the following steps of 1, extracting Chinese magnoliavine fruits with ethanol to obtain first extract fine powder; 2, distilling rhizoma acori graminei with steam to obtain volatile oil, a distilled water solution and medicinal residues, wrapping the volatile oil in cyclodextrin, and performing drying and pulverizing to form second extract fine powder; 3, adding water for decocting other components to obtain a filtrate; 4, treating the distilled water solution obtained in step 2 and the filtrate obtained in step 3 to obtain third extract fine powder; 5, mixing the extract fine powder with an additive and then performing granulating and drying to obtain the medicament for treating attention deficit hyperactivity disorder. The medicament for treating attention deficit hyperactivity disorder can achieve a high cure rate during application, and the maximum cure rate reaches 92.5%.

The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the ATP2B2 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the ATP2B2 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and / or treatment of Asperger syndrome, pervasive developmental disorder, childhood disintegrative disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.

The invention relates to methods of treating attention deficit hyperactivity disorder in patients in need thereof, and methods for selecting therapeutic dosage amounts to achieve the desired efficacy more quickly. More specifically, the methods of the present invention provide for methylphenidate treatment regimens wherein the efficacious dosage amounts are selected based upon the body weight of the patient to be treated.